BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 30661062)

  • 1. Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer.
    Lin P; Guo YN; Shi L; Li XJ; Yang H; He Y; Li Q; Dang YW; Wei KL; Chen G
    Aging (Albany NY); 2019 Jan; 11(2):480-500. PubMed ID: 30661062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an Immunogenomic Landscape-Based Prognostic Index of Head and Neck Squamous Cell Carcinoma.
    Long J; Zhang S; Zeng X; Ouyang Y; Wang Y; Hu Z; Ye Y; Wu W; Jin F; Zhou S; Zeng Z
    Front Mol Biosci; 2020; 7():586344. PubMed ID: 33330624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.
    Xiao H; Wang B; Xiong HX; Guan JF; Wang J; Tan T; Lin K; Zou SB; Hu ZG; Wang K
    J Cell Physiol; 2021 Apr; 236(4):2572-2591. PubMed ID: 32853412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma.
    Qin R; Li C; Wang X; Zhong Z; Sun C
    Cancer Cell Int; 2021 Jul; 21(1):378. PubMed ID: 34266418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer.
    Luo Y; Chen L; Zhou Q; Xiong Y; Wang G; Liu X; Xiao Y; Ju L; Wang X
    J Cell Mol Med; 2020 Nov; 24(22):13370-13382. PubMed ID: 33048468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer.
    Lin K; Huang J; Luo H; Luo C; Zhu X; Bu F; Xiao H; Xiao L; Zhu Z
    Aging (Albany NY); 2020 Mar; 12(7):5832-5857. PubMed ID: 32235004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
    Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
    BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
    Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
    BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of biomarkers associated with cervical lymph node metastasis in papillary thyroid carcinoma: Evidence from an integrated bioinformatic analysis.
    Zhang Z; Zhao S; Wang K; Shang M; Chen Z; Yang H; Chen Y; Chen B
    Clin Hemorheol Microcirc; 2021; 78(2):117-126. PubMed ID: 33554894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
    Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer.
    Wen S; Luo Y; Wu W; Zhang T; Yang Y; Ji Q; Wu Y; Shi R; Ma B; Xu M; Qu N
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1579-1589. PubMed ID: 34693452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive immunogenomic landscape analysis of prognosis-related genes in head and neck cancer.
    Li L; Wang XL; Lei Q; Sun CZ; Xi Y; Chen R; He YW
    Sci Rep; 2020 Apr; 10(1):6395. PubMed ID: 32286381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
    Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
    Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.
    Hosseinkhan N; Honardoost M; Blighe K; Moore CBT; Khamseh ME
    J Endocrinol Invest; 2020 Jul; 43(7):911-923. PubMed ID: 31965517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
    Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a prognostic index based on immunogenomic landscape analysis in glioma.
    Luo H; Tao C; Wang P; Li J; Huang K; Zhu X
    Immun Inflamm Dis; 2021 Jun; 9(2):467-479. PubMed ID: 33503296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a four immune-related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma.
    Gao X; Yang J; Chen Y
    J Cell Physiol; 2020 Dec; 235(12):9834-9850. PubMed ID: 32452055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an immune-related prognostic index associated with hepatocellular carcinoma.
    Hu B; Yang XB; Sang XT
    Aging (Albany NY); 2020 Mar; 12(6):5010-5030. PubMed ID: 32191631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.
    Kang YY; Li JJ; Sun JX; Wei JX; Ding C; Shi CL; Wu G; Li K; Ma YF; Sun Y; Qiao H
    Clin Transl Oncol; 2021 Dec; 23(12):2536-2547. PubMed ID: 34245428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.